Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04601116
Other study ID # SBMASTER
Secondary ID 2019-002508-42
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 4, 2021
Est. completion date January 1, 2035

Study information

Verified date January 2021
Source Aarhus University Hospital
Contact Signe SB Borgquist, MD, PhD
Phone 004522624525
Email signe.borgquist@auh.rm.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.


Description:

Cholesterol-lowering drugs such as statins are currently used to lower cholesterol levels and prevent cardiovascular events. Statins have, however, received substantial scientific attention as cancer-inhibiting drugs. Previous findings were recently supported in a large-scaled study again demonstrating the beneficial effects of statins on breast cancer outcome this time nested within a large, international, randomized clinical trial of modern adjuvant cancer therapy. Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. Thus, the primary objective of the MASTER trial is to determine the clinical efficacy of the statin - atorvastatin - as measured by invasive disease-free survival among patients with primary breast cancer. The trial is nationwide throughout Denmark and a total of 3,360 women are to be included in the trial. Women eligible for the trial have been diagnosed with an estrogen receptor positive breast cancer and are candidates for systemic cancer therapy, either prior to or following breast surgery. Upon eligibility and signed informed consent, trial participants will be randomized in a 1:1 manner to either standard treatment and atorvastatin 80 mg/day or standard treatment and placebo. The randomization is blinded. The treatment with atorvastatin or placebo will continue for two years unless side effects are experienced and further treatment with atorvastatin or the placebo is deemed inadequate. The standard treatment will of course continue as planned. The trial participants will follow the standard clinical routines in terms of follow-up and in addition they are asked to fill in questionnaires, i.e. regarding potential side effects or new events or diagnoses, up to ten years following inclusion. Potential breast cancer recurrences are hereby identified and a follow-up of at least 61/2 years will be required for the trial the demonstrate the estimated clinical difference between the randomized groups of patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 3360
Est. completion date January 1, 2035
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Patients must meet ALL of the following criteria to be eligible for randomization: Inclusion Criteria: 1. Women with estrogen receptor positive breast cancer who are candidates for (neo)adjuvant systemic therapy OR have received =3 years of adjuvant endocrine therapy. 2. Age > 18 years. 3. Performance status of ECOG = 2. 4. Prior to patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations. Patients meeting ANY one of the following criteria are not eligible: Exclusion Criteria: 1. History of any prior (ipsi- and/or contralateral) invasive breast carcinoma. 2. Ongoing (prevalent) cholesterol-lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors). If so, the patient can be enrolled in the observational arm. 3. Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level more than three times the upper limit of the normal range). 4. Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption AND creatine kinase (CK) measured to less than five times the upper limit (CK only measured in case of predisposing factors). 5. No current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or gemfibrozile, cyclosporin or danazol. 6. Pregnancy or breast-feeding. 7. Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial. 8. History of allergic reactions attributed to compounds of similar chemical or biological composition to atorvastatin.

Study Design


Intervention

Drug:
Atorvastatin 80 Mg Oral Tablet
Atorvastatin 80 mg per day for 2 years
Placebo oral tablet
Placebo 1 tablet per day for 2 years

Locations

Country Name City State
Denmark Aarhus University Hospitak Aarhus

Sponsors (11)

Lead Sponsor Collaborator
Aarhus University Hospital Aalborg University Hospital, Bornholms Hospital, Herning Hospital, Naestved Hospital, Nordsjaellands Hospital, Odense University Hospital, Rigshospitalet, Denmark, Sygehus Sønderjylland, University of Copenhagen, Vejle Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Invasive disease-free survival Invasive disease-free survival (IDFS), defined as the time from randomization until the date of the first occurrence of one of the following events:
Ipsilateral invasive breast tumor recurrence: invasive breast cancer involving the same breast parenchyma as the original primary.
Regional invasive breast cancer recurrence: Invasive breast cancer in the axilla, regional lymph nodes, chest wall, and skin of the ipsilateral breast.
Distant recurrence: Metastatic disease-breast cancer that has either been biopsy confirmed or clinically diagnosed as recurrent invasive breast cancer.
Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause.
Contralateral invasive breast cancer.
Second primary non-breast invasive cancer.
10 years
Secondary Distant-recurrence free interval Distant-recurrence free interval defined as time from inclusion to first distant recurrence including associations with first site of recurrence. 10 years
Secondary Recurrence-free interval Recurrence-free interval including associations with first site of recurrence 10 years
Secondary Overall survival. Overall survival. 10 years
Secondary Incidence of Treatment-Emergent Adverse Events as assessed by CTC-AE, 5.0 Incidence of Treatment-Emergent Adverse Events as assessed by CTC-AE, 5.0 10 years
Secondary Cardiac death-free interval Cardiac death-free interval. Cardiac death is defined as:
Definitive cardiac death due to heart failure, myocardial infarction or documented primary arrhythmia.
Probable cardiac death: Probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.
10 years
Secondary Co-morbidity Co-morbidity incidence beyond cardiovascular events during follow-up including diagnoses such as diabetes mellitus. 10 years
See also
  Status Clinical Trial Phase
Completed NCT03080623 - Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
Completed NCT05527769 - Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
Completed NCT06376578 - Exercise Interventions for Improving Health in Breast Cancer Survivors N/A
Completed NCT03004534 - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Early Phase 1
Recruiting NCT05020574 - Microbiome and Association With Implant Infections Phase 2
Active, not recruiting NCT06277141 - The Vitality Mammography Messaging Study N/A
Completed NCT03555227 - USG PECS vs LIA for Breast Cancer Surgery N/A
Completed NCT03270111 - High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women N/A
Active, not recruiting NCT03917082 - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Phase 2
Recruiting NCT05561842 - Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Completed NCT04554056 - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF Phase 2/Phase 3
Active, not recruiting NCT03127995 - Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence N/A
Active, not recruiting NCT02237469 - Prone Breast Radiotherapy Treatment Planning Observational Study
Completed NCT01204125 - Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Phase 2
Recruiting NCT04565054 - Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC Phase 3
Not yet recruiting NCT06412133 - Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients N/A
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Recruiting NCT06087120 - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting NCT06058936 - Exercises Using Virtual Reality on Cancer Patients N/A
Completed NCT03470935 - Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger